Theravance Biopharma (TBPH) Misses Q1 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Theravance Biopharma, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update
May 5, 2022 4:05 PM EDTImplied 35% share of YUPELRI® (revefenacin) net sales1: $15.3M Q1 2022 up 19% from Q1 2021TRELEGY Q1 2022 global net sales: $454M, up 33% from Q1 20212Results from a Phase 3 study of ampreloxetine showed a benefit in study patients with multiple system atrophy (MSA) Restructuring process completed in Q1 2022
DUBLIN, May 5, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the first quarter of 2022.
... More